What's in Taiho Oncology, Inc.'s pipeline?

Taiho Oncology, Inc. has 13 drugs in our index: 2 marketed, 0 filed, 3 in Phase 3, 3 in Phase 2, 5 in Phase 1.

Which companies overlap with Taiho Oncology, Inc.'s portfolio?

Top competitors by shared drug class: Allist Pharmaceuticals, Inc., Assistance Publique - Hôpitaux de Paris, Bayer, Beta Pharma Shanghai, Betta Pharmaceuticals Co., Ltd..

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/taiho-oncology-inc.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-05-16 · How we verify

Taiho Oncology, Inc. — Portfolio Competitive Intelligence Brief

Taiho Oncology, Inc. pipeline: 2 marketed, 0 filed, 3 Phase 3, 3 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

2 marketed 0 filed 3 Phase 3 3 Phase 2 5 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

Drug	Generic	Phase	Class	Target	Area	First approval
Lonsurf	TIPIRACIL	marketed	Nucleoside Analog Antiviral [EPC]	Thymidine phosphorylase	Oncology	2015-01-01
CPT-11	CPT-11	marketed			Oncology
TAS6417	TAS6417	phase 3	TGF-β receptor inhibitor	ALK5 (activin receptor-like kinase 5)	Oncology
ASTX727	ASTX727	phase 3	Hypomethylating agent	DNA methyltransferase (DNMT)	Oncology
TAS-120	TAS-120	phase 3	FGFR inhibitor	FGFR (Fibroblast Growth Factor Receptor)	Oncology

Therapeutic area mix

Oncology · 5
Other · 1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

2029-09-22 — Lonsurf · RE46284 · US
2034-06-17 — Lonsurf · 10457666 · US
2034-06-17 — Lonsurf · 9527833 · US
2034-09-05 — Lonsurf · 9943537 · US
2037-02-03 — Lonsurf · 10456399 · US
2037-02-03 — Lonsurf · 10960004 · US

Competitive overlap (companies sharing drug classes)

Allist Pharmaceuticals, Inc. · 1 shared drug class
Assistance Publique - Hôpitaux de Paris · 1 shared drug class
Bayer · 1 shared drug class
Beta Pharma Shanghai · 1 shared drug class
Betta Pharmaceuticals Co., Ltd. · 1 shared drug class
Bio-Path Holdings, Inc. · 1 shared drug class
Caliway Biopharmaceuticals Co., Ltd. · 1 shared drug class
AbbVie (prior sponsor, Abbott) · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Taiho Oncology, Inc.:

Cite this brief

Drug Landscape (2026). Taiho Oncology, Inc. — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/taiho-oncology-inc. Accessed 2026-05-16.